Cipla Ltd (CIPLA)

Cipla Recalls Inhalation Solution Due to Manufacturing Issues; Demonstrates Robust Uptrend - 06 May, 2024

Cipla is recalling inhalation solution from the US market due to manufacturing issues. Meanwhile, Cipla's stock has demonstrated a robust uptrend on a weekly scale, indicating sustained upward momentum and bullish sentiment.

Cipla Recalls Asthma Medication in the US - 05 May, 2024

Cipla's New Jersey-based subsidiary is recalling over 59,000 packs of asthma medication from the US market due to manufacturing issues related to short fill. The recalled drug is used to help control the symptoms of lung diseases.

Cipla Ltd Shows Strong Growth and Insider Interest - 03 May, 2024

Cipla Ltd has shown strong growth in EPS, EBIT margins, and revenues over the past three years. Company insiders have also invested meaningfully in the stock, making it worth watching for investors.

Indian Pharma Companies to Benefit from Patent Cliff and Short Supply of Key Drugs - 02 May, 2024

Unmesh Sharma, Head of Institutional Equities at HDFC Securities, expects Sun Pharma, Dr Reddys Labs, Cipla and Aurobindo Pharma to benefit from the patent cliff and short supply of key drugs due to suboptimal profitability, creating incremental revenue opportunities for Indian players.

Cipla Stock Analysis & Trading Strategies - 30 Apr, 2024

Cipla's stock is in a long-term uptrend and expected to reach the Rs 1,500 resistance level. Traders can buy now at Rs 1,407 and deploy a Debit Spread strategy suggested by Madhu Bansal for steady income. Maximum profit stands at Rs 34,000 with maximum loss at Rs 17,500.

Cipla Subsidiary Completes Purchase of Distribution Business - 29 Apr, 2024

Cipla Health, a wholly-owned subsidiary of Cipla Ltd, has completed the purchase of the distribution and marketing business undertaking of cosmetics and personal care business from Ivia Beaute Private Limited through a slump sale arrangement.

Investec Initiates Long FAST on Cipla Stock - 25 Apr, 2024

Investec has initiated a long FAST on Cipla stock, citing key pipeline assets delivery and improvement in US generic macro. Despite anticipation of weak Q4 results and competition from Amneal, Cipla remains Investec's preferred pick in the largecap pharma space.

Investec Maintains Buy Rating on Cipla with Raised Target Price - 24 Apr, 2024

Brokerage firm Investec maintains a buy rating on Cipla despite the recent decline in its stock value due to anticipation surrounding Amneal's potential entry into the market with a competitive offering of Albuterol. Investec sees limited impact on EPS even in the face of new competition and envisions the possibility of upgrades for FY25 and FY26. The brokerage firm has raised the target price to Rs 1550 per share.

Cipla Fined for Inadmissible Credit Claim - 19 Apr, 2024

Pharmaceutical company Cipla Ltd has been fined Rs 1.83 crore by the GST authority for claiming inadmissible transitional credit on education cess.

Cipla Acquires Cosmetics Business, ICICI Sets Target Price - 17 Apr, 2024

Cipla acquires Ivia Beaute's cosmetics and personal care distribution business for Rs 130 crore. ICICI Securities sets a buy call on Cipla with a target price of Rs 1,660 per share.

Cipla Acquires Cosmetics Business of Ivia Beaute - 16 Apr, 2024

Cipla Health Limited has signed a business transfer agreement to purchase the distribution and marketing business undertaking of Ivia Beaute Private's cosmetics and personal care business, which includes brands like Astaberry, Ikin, and Bhimsaini on a worldwide basis. The acquisition cost is set at ₹130 crore.

Cipla's Subsidiary Acquires Cosmetics Business; Technical Analysis Suggests Weakness - 15 Apr, 2024

Cipla Health Limited, a subsidiary of Cipla, has acquired the distribution and marketing business of Ivia Beaute Private Ltd for Rs 130 crore. However, technical analysis suggests further weakness in Cipla stock due to a confirmed Double Top pattern and negative divergence observed in RSI.

Cipla Ltd's Ownership Structure Analyzed by Experts - 12 Apr, 2024

Experts analyze Cipla Ltd's ownership structure, with institutions holding a 39% stake and insiders owning a reasonable proportion. Deven Choksey believes that Cipla offers clarity from the point of view of complex genetics and growth.

Cipla Receives Six Observations from USFDA - 10 Apr, 2024

The USFDA issued six observations for Cipla's Patalganga unit following a cGMP inspection. The company stated that it will work closely with the FDA to address these concerns within the stipulated timeframe. Cipla shares ended 1% lower at ₹1,449 and have declined in five out of the last six trading sessions.

Sanofi Forms Strategic Alliances with Cipla and Other Indian Pharma Firms - 07 Apr, 2024

Sanofi has partnered with prominent Indian pharmaceutical companies, including Cipla, to expand the market penetration of its products in India. The collaborations aim to maximize the impact of existing products and extend their reach across the country.